Engineered immune cells take on childhood leukemia in groundbreaking trial

NCT ID NCT06064903

Recruiting now Disease control Sponsor: Bambino Gesù Hospital and Research Institute Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 20 times

Summary

This study tests a new treatment called CD7-CART01 for children with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard therapy. The treatment uses the child's own immune cells, modified to target and kill cancer cells. The goal is to find the safest dose and see how well it works, with 26 children expected to take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ospedale Pediatrico Bambino Gesù
RECRUITING

Rome, Rome, 00165, Italy

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

T CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA